Amanat Acquisition

The filing establishes the definitive economic framework, redemption parameters, and conflict-of-interest landscape for pre-deal capital markets participants. Management discloses a targeted focus on healthcare and life science companies, highlighting prior tenures at entities like Zura Bio, Tourmaline Bio, and Liminatus Pharma, while simultaneously cautioning that historical performance does not guarantee future deal sourcing success or return on capital. The capital structure structurally advantages insiders: founders secured equity at roughly $0.012 per share, carry anti-dilution conversion mechanics that can expand their post-combination voting and economic stakes beyond the baseline 20%, and receive a recurring $20,000 per month administrative service fee alongside firm minimum compensation guarantees for executive leadership. These terms create immediate implied value dilution for public investors, with pro forma adjusted net tangible book value per share models projecting outlays ranging from approximately $2.32 to $10.44 per share depending on hypothetical redemption tranches. Notably, the deliberate omission of warrants eliminates traditional SPAC post-merger hedging overhang but also removes a built-in upside component for early buyers. The precise redemption cap, extension triggers, and over-allotment-based founder share forfeiture rules provide transparent liquidity boundaries while directly aligning sponsor retention incentives with the scale of capital successfully deployed.

These finalized terms remove ambiguity around liquidity, capital preservation, and sponsor alignment prior to the IPO. The $75,000,000 trust baseline and explicit 24-month liquidation trigger define the maximum redemption value and timeline risk for public shareholders. The shift of the $0.30-per-share deferred discount to public shareholders upon a missed deadline effectively increases the cash available for redemption in a failure scenario, but also underscores the cost of inaction. The 80% fair market value threshold and capped $20,000 monthly sponsor payouts establish clear guardrails against excessive dilution or administrative drain during the search period. Together, these exhibits confirm standard but binding mechanical protections that will govern the trust, redemption deadlines, and post-combination equity structure.

Defines the baseline investment thesis and economic mechanics for public capital: investors receive equity-only exposure without accompanying public warrants, establishing a clear $10.00-per-share redemption floor but introducing substantial immediate dilution given the nominal sponsor share cost. The filing explicitly links capital deployment to a life sciences/biotech sourcing mandate backed by management's documented prior de-SPAC track records, while structuring governance (corporate opportunity renunciation, extended voting windows, and insider non-redeeming commitments) to align sponsor incentives with deal execution within the prescribed timeframe.

The baseline trust composition and the 24-month execution timeline impose strict capital deployment discipline, while the 20% redemption cap and automatic extension redemption rights structurally limit holdout leverage and preserve deal viability. Because the sponsor acquired founder shares at nominal cost and waived liquidation rights, the economic incentive heavily favors accelerating a combination within the window, despite the filing's acknowledgment of potential conflicts arising from board members' simultaneous fiduciary duties to other entities and broad corporate opportunity waivers.

What changed: A Schedule 13G joint filing agreement pursuant to Rule 13d-1(k) executed by Affinity Asset Advisors, LLC and Michael Cho. Per the agreement signed by Affinity Asset Advisors, LLC and Michael Cho, the parties established a joint reporting arrangement for future Schedule 13G amendments, with each accepting shared responsibility for timely submission while retaining individual liability for the completeness and accuracy of their own information. The filing discloses no aggregate share count, beneficial ownership percentage, or voting/disposition rights. It contains no reference to Amanat Acquisition’s trust account, leaves the $10.04 per share trust balance untouched, does not pause or alter the May 18, 2028 deadline, reports zero advancement toward a business combination during the SEARCHING phase, and identifies no shifts in sponsor conduct or corporate governance beyond the procedural joint filing setup. Why it matters: For investors monitoring redemption windows, trust preservation, or merger progress, the document carries no mechanical impact: the deadline timeline continues unadjusted, the trust value remains fixed at $10.04, and no sponsor or management actions modify the SEARCHING mandate. The only relevant detail pertains to potential institutional ownership aggregation, though the specific block size triggering the 13G threshold is omitted. Because Affinity Asset Advisors, LLC and Michael Cho made no claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel, the filing offers no fundamental update to Amanat Acquisition’s valuation thesis or liquidity expectations.

What changed: A Schedule 13D/A, identified in the filing header as a 'beneficial ownership report,' which functions as a routine regulatory amendment to update previous Section 13(d) disclosures when a person or group alters holdings exceeding five percent of a registrant's voting securities. The extracted text contains only the title line and a system notation reading 'Structured holder table not present in this XML variant.' No acquirer name, share count, transaction price, or effective amendment date appears in the provided text. Mechanically, a 13D/A indicates a post-initial filing adjustment to the >5% ownership threshold. For a search-phase SPAC, such an amendment typically reflects modified common equity or warrant positions held by founders, anchor investors, or coordinated groups. The document does not report alterations to any redemption calendar, trust distribution mechanics, extension proposals, or sponsor governance conduct. Why it matters: Because the required tabular schedule is omitted, investors cannot verify updated ownership percentages, calculate trailing economic exposure, or determine if any position crosses or drops below the statutory 5% reporting boundary that governs proxy solicitation rights. The amendment nonetheless signals ongoing positional activity that could affect future lock-up expirations, secondary trading liquidity, and sponsor alignment ahead of any target announcement. The text contains zero references to customer backlogs, contracted revenue, total addressable market sizing, commercialization strategies, proprietary technology, channel partnerships, pending litigation, or key personnel appointments. Without the numerical breakdown, the filing provides procedural transparency but yields no quantifiable inputs to stress-test against redemption triggers or enterprise valuation models.

What changed: A Form 4 insider ownership report submitted to the SEC for Amanat Acquisition Corp. According to the filing, Amanat Sponsor Holdings LLC (identified in the document as a 10% owner) reported no acquisitions, dispositions, or derivative securities exercises or cancellations. The trust value of $10.04 per share and the 2028-05-18 liquidation deadline remain untouched by this submission. Deal progress continues to be classified as SEARCHING, with no target acquisition, extension amendment, redemption window opening, or underwriter commitment disclosed in the text. Why it matters: For investors monitoring redemption calendars, trust stability, and sponsor conduct, the explicit certification of zero reported transactions confirms the sponsor’s equity stake has not been traded, pledged, or diluted. In a SEARCHING SPAC, a static Form 4 removes short-term liquidity overhang and indicates the sponsor is preserving capital alignment ahead of any future merger negotiation or extension vote. Because the filing introduces no timeline shifts, capital calls, or strategic pivots, it does not alter the trajectory toward the 2028-05-18 deadline or shift pressure on the $10.04 trust floor. Investors should treat the submission as a neutral compliance checkpoint; absent subsequent target announcements or extension filings, redemption dynamics and valuation mechanics remain unchanged until material corporate action is formally disclosed.

What changed: This document IS a Form 4 insider ownership report, a routine regulatory compliance exhibit filed to disclose changes in equity or derivative holdings by an issuer’s officers, directors, or principal stockholders. According to the filing text, the document reports no mechanical shifts bearing on redemption deadlines, trust value, extension votes, deal progress, or sponsor conduct. It states that Reporting Person Kulkarni Sandeep Chidambar—identified as a director, Director and Chairman, and 10% owner—has recorded ‘No non-derivative transactions or holdings reported.’ Beyond this administrative confirmation of zero transactional activity, the document contains no additional substance: it makes no claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel adjustments. Why it matters: For investors tracking redemption mechanics, trust continuity, extension timelines, de-spacings, and sponsor behavior, this filing establishes a transactional baseline: the chairman and 10% stakeholder neither accumulated nor divested securities during the reporting window. In a SPAC maintaining a SEARCHING designation, the null report indicates no shift in capital alignment or insider signaling ahead of any future deadline or trust distribution. While it updates neither the redemption calendar nor the trust composition, it documents stable sponsor positioning and provides a benchmark for monitoring subsequent insider trades.

What changed: A Joint Filing Agreement (Exhibit 99.1) submitted as part of an amended Schedule 13G, formally consolidating the Section 13 reporting obligations of RP Investment Advisors LP and RP Select Opportunities Master Fund Ltd. under the Securities Exchange Act of 1934. The document establishes a shared filing protocol for two affiliated investment vehicles governed by RP Investment Advisors GP Inc., executed by Chief Executive Officer Richard Pilosof. As this excerpt contains only the procedural agreement and not the primary Schedule 13G data pages, no revised share counts, ownership percentages, or acquisition purpose statements are presented. Consequently, no alteration is documented for AMAN’s redemption window, $10.04 per share trust balance, 2028-05-18 liquidation deadline, or ongoing searching status. The SPAC’s operational timeline, sponsor fiduciary commitments, and business combination pipeline remain untouched by this filing. Why it matters: The agreement reveals institutional alignment between two funds sharing the same general partner, indicating a coordinated reporting structure that may simplify or consolidate future proxy voting and shareholder communications around any eventual proposed transaction. For investors monitoring redemption mechanics and block positioning, this clarifies how affiliated capital pools will aggregate their public disclosures ahead of a special meeting. Because the submission is strictly administrative and omits the substantive Schedule 13G body, it provides no actionable intelligence on redemption volume, trust yield, extension voting thresholds, or deal progression. Tracking the actual share quantity and filing date triggers requires the accompanying Schedule 13G form itself.

What changed: A Joint Filing Agreement (Exhibit I) appended to a Schedule 13G/A, executed on July 31, 2026, by Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, confirming they will submit a single amended Schedule 13G to report combined beneficial ownership of Amanat Acquisition Corp Class A Ordinary Shares (par value $0.0001 per share) pursuant to SEC rules. According to the filing agreement signed by Global General Counsel Gil Raviv on behalf of the corporate filers and by Israel A. Englander individually, the undersigned parties authorize consolidated regulatory disclosure under Rule 13d-1(k). The exhibit discloses no updated share quantities, acquisition timestamps, or transaction pricing, meaning there are no alterations to the SPAC’s trust composition, redemption mechanics, or business combination timetable introduced by this submission. Why it matters: This routine compliance attachment confirms aggregated institutional positioning by Millennium-affiliated entities but contains zero substantive commentary on target acquisition progress, sponsor conduct, customer relationships, revenue projections, market sizing, technological capabilities, partnership arrangements, litigation exposure, or executive personnel changes. Because the document furnishes neither operational metrics nor forward-looking statements, it provides no actionable intelligence for calculating redemption yields, assessing extension vote triggers, or evaluating sponsor fiduciary behavior. Investors receive only a standardized confirmation of shared beneficial ownership tracking.

What changed: Routine compliance exhibit (Form 10-Q Quarterly Report). The registrant states via Subsequent Events disclosure that on May 20, 2026, it consummated an Initial Public Offering of 7,500,000 Class A Ordinary Shares at $10.00 per share, generating $75,000,000 in gross proceeds. The filing further notes that $75,000,000 was deposited into the Trust Account upon closing. Management indicates that the entity has established a 24-month Completion Window from the IPO date to finalize a Business Combination. Why it matters: These disclosures dictate the economic mechanics for public investors: the Trust Account balance of $75,000,000 establishes the initial redemption floor. The 24-month deadline fixes the expiration of the search period, after which liquidation procedures trigger. Regarding sponsor conduct, the registrant discloses a $20,000 per month administrative support agreement commencing May 18, 2026, and notes that the Sponsor, officers, and directors have contractually waived redemption rights for their Founder and Private Placement Shares. Deal progress remains static; management confirms the company has not selected a target nor engaged in substantive discussions regarding an initial Business Combination.

What changed: A Joint Filing Agreement (Exhibit 99.1) attached to a Schedule 13G beneficial ownership report, executed pursuant to Section 13 and Section 16 of the Securities Exchange Act of 1934. According to the joint filing agreement dated June 16, 2026, RP Investment Advisors LP and RP Select Opportunities Master Fund Ltd. authorized centralized disclosure administration, permitting both entities to submit a single Schedule 13G while preserving independent compliance duties. The exhibit was executed by Richard Pilosof in his capacity as Chief Executive Officer of RP Investment Advisors LP. The document contains no references to SPAC AMAN’s redemption schedule, trust value, proposed business combination deadline, extension procedures, merger progress, or sponsor behavior. No shift in beneficial ownership percentage, acquisition timing, or voting posture is disclosed within this exhibit; those data points are entirely absent. Why it matters: The joint filing confirms coordinated institutional positioning behind Amanat Acquisition, indicating that RP Investment Advisors LP and RP Select Opportunities Master Fund Ltd. collectively meet the Section 13(d) reporting threshold and have consolidated their regulatory footprint under Richard Pilosof’s executive direction. For investors monitoring redemption pressure, extension votes, or sponsor alignment ahead of the relevant business combination window, this document establishes a known blockholder base but provides zero visibility into share counts, tender intentions, or liquidity dynamics. Subsequent 13G/D amendments from these parties will dictate whether this affiliate group intends to passively hold, seek board representation, or participate in future redemption elections, directly informing capital structure stress tests and governance risk assessments.

What changed: A Joint Filing Agreement (Exhibit 99.1) attached to a Schedule 13D beneficial ownership report, dated June 11, 2026. This filing contains no updates to redemption deadlines, trust value mechanics, extension timelines, deal progress, or sponsor conduct. It is a routine compliance exhibit confirming that Amanat Sponsor Holdings LLC and Sandeep Kulkarni have agreed, pursuant to Rule 13(d)(1)(k), to file a single Schedule 13D on behalf of both parties to disclose their collective beneficial ownership of Amanat Acquisition Corp Class A ordinary shares. The agreement explicitly states it may be terminated by either party upon one week’s prior written notice or a mutually consented shorter period. Why it matters: No substantive claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel are present in this document; the terms described are solely contractual provisions stated by the Filers within the exhibit itself. For investors tracking SPAC mechanics, this exhibit signals regulatory alignment between the sponsor entity and its Managing Member, which often accompanies unified voting arrangements or block positioning ahead of the 2028-05-18 deadline or any proposed business combination. Because this is only the supporting joint filing agreement, the actual share counts, acquisition purposes, and identity-of-interest disclosures that dictate redemption or conversion behavior remain in the primary Schedule 13D statement, which is not included here.

What changed: A Schedule 13G beneficial ownership report identifying six affiliated Sculptor Capital entities as holders of Amanat Acquisition securities. This filing discloses no operational or financial updates regarding Amanat Acquisition. It contains only holder names and SEC receipt metadata. Regarding redemption mechanics, trust valuation, extension windows, deal progress, or sponsor conduct, the text provides zero quantitative data on share counts, percentage ownership, acquisition dates, voting/investment power changes, or stated transaction purposes. Without these mandated disclosures, the filing offers no visibility into how institutional accumulation may impact per-share trust distributions, alter shareholder vote thresholds ahead of the announced deadline, or indicate sponsor runway pressures. Why it matters: Schedule 13G filings typically mark the threshold where passive or active institutional capital crosses into significant economic exposure, often preceding merger speculation or proxy activity. While this specific excerpt flags Sculptor Capital’s involvement, the absence of disclosure language prevents assessment of whether these positions represent long-term trust preservation, targeted warrant/call option positioning, or preparatory accumulation for a forthcoming business combination announcement. Until the complete filing—including exact security classes, transaction dates, and purpose statements—is reviewed, investors cannot determine if this ownership shift materially changes liquidity dynamics, redemption floor calibration, or partnership negotiations with potential targets.